Literature DB >> 10871859

Cloning of an isoform of integrin-linked kinase (ILK) that is upregulated in HT-144 melanoma cells following TGF-beta1 stimulation.

B Janji1, C Melchior, L Vallar, N Kieffer.   

Abstract

We have shown previously that integrin-linked kinase (ILK) is upregulated in human HT-144 melanoma cells following TGF-beta1 stimulation. Using mRNA from TGF-beta1 stimulated HT-144 cells and reverse transcriptase polymerase chain reaction, we have isolated a cDNA encoding a protein highly homologous to ILK. Sequencing of the full-length 1359 base pair cDNA and polypeptide translation revealed that this protein, designated ILK-2, differs from the known ILK (hereafter called ILK-1) by only four amino acids, while the cDNA sequence diverges by 102 nucleotides, thus excluding that ILK-2 is an allelic variant of ILK-1. Expression of ILK-2 mRNA was observed in metastatic human HT-144 melanoma and HT-1080 fibrosarcoma cell lines, but not in normal human tissues. Moreover, stimulation of HT-144 cells with TGF-beta1, but not with EGF, PDGF-AB or insulin, induced a selective overexpression of ILK-2 mRNA as compared to ILK-1 mRNA. Bacterially-expressed GST/ILK-2 autophosphorylated and labeled myelin basic protein as well as a recombinant GST/beta3 integrin cytoplasmic tail peptide. Transfection of either ILK-2 or ILK-1 cDNA into the non-metastatic melanoma cell line SK-Mel-2, expressing exclusively ILK-1, induced anchorage independent cell growth and cell proliferation, as demonstrated by growth in soft agar. Our data provide evidence that ILK-2 is a new isoform of ILK-1 that is expressed in some highly invasive tumor cell lines but not in normal adult human tissues and whose expression is regulated by TGF-beta1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871859     DOI: 10.1038/sj.onc.1203640

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis.

Authors:  M P Scheid; J R Woodgett
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

2.  Integrin-linked kinase functions as a downstream signal of platelet-derived growth factor to regulate actin polymerization and vascular smooth muscle cell migration.

Authors:  Mitra Esfandiarei; Sahar Abdoli Yazdi; Virginia Gray; Shoukat Dedhar; Cornelis van Breemen
Journal:  BMC Cell Biol       Date:  2010-02-23       Impact factor: 4.241

3.  Tanshinone IIA reduces macrophage death induced by hydrogen peroxide by upregulating glutathione peroxidase.

Authors:  Yu-I Li; Gary Elmer; Renée C Leboeuf
Journal:  Life Sci       Date:  2008-08-16       Impact factor: 5.037

4.  Tumor expression of integrin-linked kinase (ILK) correlates with the expression of the E-cadherin repressor snail: an immunohistochemical study in ductal pancreatic adenocarcinoma.

Authors:  David F Schaeffer; Kiran Assi; Katie Chan; Andrzej K Buczkowski; Stephen W Chung; Charles H Scudamore; Alan Weiss; Bill Salh; David A Owen
Journal:  Virchows Arch       Date:  2010-01-21       Impact factor: 4.064

5.  Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis.

Authors:  Yingjian Li; Junwei Yang; Chunsun Dai; Chuanyue Wu; Youhua Liu
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

6.  Modulation of integrin-linked kinase (ILK) expression in human oesophageal squamous cell carcinoma cell lines by the EGF and TGFbeta1 growth factors.

Authors:  Glenn A Driver; Robin B Veale
Journal:  Cancer Cell Int       Date:  2006-04-27       Impact factor: 5.722

Review 7.  Integrin-linked kinase (ILK): the known vs. the unknown and perspectives.

Authors:  Agata Górska; Antonina Joanna Mazur
Journal:  Cell Mol Life Sci       Date:  2022-01-28       Impact factor: 9.261

8.  Genomic analysis of the eukaryotic protein kinase superfamily: a perspective.

Authors:  Steven K Hanks
Journal:  Genome Biol       Date:  2003-04-29       Impact factor: 13.583

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.